FCCC LOGO Faculty Publications
Malinow MR , Duell PB , Hess DL , Anderson PH , Kruger WD , Phillipson BE , Gluckman RA , Block PC , Upson BM
Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease
New England Journal of Medicine. 1998 Apr 9;338(15) :1009-1015
PMID: ISI:000072969500001   
Back to previous list
Abstract
Background The Food and Drug Administration (FDA) has recommended that cereal-grain products be fortified with folic acid to prevent congenital neural-tube defects. Since folic acid supplementation reduces levels of plasma homocyst(e)ine, or plasma total homocysteine, which are frequently elevated in arterial occlusive disease, we hypothesized that folic acid fortification might reduce plasma homocyst(e)ine levels. Methods To test this hypothesis, we assessed the effects of breakfast cereals fortified with three levels of folic acid, and also containing the recommended dietary allowances of vitamins B-6 and B-12, in a randomized, double-blind, placebo- controlled, crossover trial in 75 men and women with coronary artery disease. Results Plasma folic acid increased and plasma homocyst(e)ine decreased proportionately with the folic acid content of the breakfast cereal. Cereal providing 127 mu g of folic acid daily, approximating the increased daily intake that may result from the FDA's enrichment policy, increased plasma folic acid by 30.8 percent (P = 0.045) but decreased plasma homocyst(e)ine by only 3.7 percent (P = 0.24). However, cereals providing 499 and 665 mu g of folic acid daily increased plasma folic acid by 64.8 percent (P < 0.001) and 105.7 percent (P = 0.001), respectively, and decreased plasma homocyst(e)ine by 11.0 percent (P < 0.001) and 14.0 percent (P = 0.001), respectively. Conclusions Cereal fortified with folic acid has the potential to increase plasma folic acid levels and reduce plasma homocyst(e)ine levels. Further clinical trials are required to determine whether folic acid fortification may prevent vascular disease. Until then, our results suggest that folic acid fortification at levels higher than that recommended by the FDA may be warranted. (C) 1998, Massachusetts Medical Society.
Notes
Times Cited: 176 English Article ZG134 N ENGL J MED